Evidence map›Paper›PMID 42856924›Full record

ReviewFrontiers in medicine2026

PSMA-targeted radioligand therapy with beta emitters in prostate cancer: current evidence, emerging indications, combination strategies, and future directions.

Hiba Noamen, Adam Bekkhoucha, Alice Bernard Tessier, Khali Trabelsi, Mehdi Borsali, Natacha Naoun, Macarena Rey-Cardenas, Alessia Daverio, Ronan Flippot, Cedric Pobel and 12 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Hiba NoamenDepartment of Nuclear Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.
Adam BekkhouchaDepartment of Nuclear Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.
Alice Bernard TessierDepartment of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.
Khali TrabelsiDepartment of Nuclear Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.
Mehdi BorsaliDepartment of Nuclear Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.
Natacha NaounDepartment of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.
Macarena Rey-CardenasDepartment of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.
Alessia DaverioDepartment of Nuclear Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.
Ronan FlippotDepartment of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.
Cedric PobelDepartment of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.
Lison FerreolRadiopharmacy Unit, Pharmacy Department, Gustave Roussy, Paris Saclay University, Villejuif, France.
Anna PatrikidouDepartment of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.
Solenn BarraudDepartment of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.
Jacopo UlianoDepartment of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.
Alexandre MegherbiDepartment of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.
Mario TerlizziDepartment of Radiotherapy, Gustave Roussy, Paris Saclay University, Villejuif, France.
Laurence AlbigesDepartment of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.
Pierre BlanchardDepartment of Radiotherapy, Gustave Roussy, Paris Saclay University, Villejuif, France.
Mario DipalmaDepartment of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.
Yohann LoriotDepartment of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.
Camilo Garcia *Department of Nuclear Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.
Désirée Deandreis *Department of Nuclear Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) has emerged as a major therapeutic advance in metastatic castration-resistant prostate cancer (mCRPC), The phase III VISION trial demonstrated that [

Indexed as

beta emittersprostate cancerradiopharmaceutical therapiestargeted radioligand therapy (TRT)theranosctics

Identifiers

PMID42856924
PMCPMC13650470

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.